The global inosine pranobex market is expected to reach US$ 234.5 million by 2028, growing at a CAGR of 2.2%. The growth of the market is attributed to the increasing prevalence of respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, and influenza. Inosine pranobex is a drug that has been shown to be effective in the treatment of these diseases.

Inosine pranobex (IP) is an antiviral and immunomodulatory drug used to treat a variety of viral infections, including subacute sclerosing panencephalitis (SSPE), herpes simplex virus (HSV), human immunodeficiency virus (HIV), human papillomavirus (HPV), influenza, and acute respiratory infections. IP is available in tablet and syrup form.

Discover Our Expert Analysis with Our Sample Report! https://absolutemarketresearch.com/Global-Inosine-Pranobex-Market/2037/request-sample

Inosine Pranobex is an antiviral medication used to treat respiratory infections, including the common cold and the flu. It is also used to prevent respiratory infections in people who are at high risk. Inosine Pranobex is not a cure for the common cold or the flu, but it can help to shorten the duration of the illness and reduce the severity of symptoms.

Key Takeaways:

  • The global inosine pranobex market is expected to reach US$ 234.5 million by 2028, growing at a CAGR of 2.2%.
  • The market is driven by the increasing prevalence of viral infections and the growing demand for immunomodulators.
  • Asia Pacific is expected to be the fastest-growing regional market, due to the large and growing population and the rising prevalence of viral infections.
  • The tablets segment is expected to be the largest segment of the market, due to their ease of use and convenience.

Regional Outlook:

  • North America: The North American inosine pranobex market is expected to grow at a CAGR of 1.5% from 2023 to 2028.
  • Europe: The European inosine pranobex market is expected to grow at a CAGR of 2.0% from 2023 to 2028.
  • Asia Pacific: The Asia Pacific inosine pranobex market is expected to grow at a CAGR of 3.0% from 2023 to 2028.
  • South and Central America: The South and Central American inosine pranobex market is expected to grow at a CAGR of 2.5% from 2023 to 2028.

Key Players:

  • Newport Pharmaceuticals
  • Gedeon Richter
  • Mochida
  • Sanofi-Aventis
  • Yung Shin
  • Sigma-Tau
  • Polfarmex
  • Sanfer
  • Meprofarm
  • Novell Pharmaceutical
  • Aflofarm

Market Segmentation:

The inosine pranobex market is segmented by type, application, and geography.

Type:

  • Tablets
  • Syrup

Application:

  • Immunomodulation
  • Antiviral applications
  • Others

Geography:

  • North America
  • Europe
  • Asia Pacific
  • South and Central America